Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM TSE:OLY NASDAQ:PTF NYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.92-3.0%$8.25$2.51▼$39.95$2.23M0.8964,910 shs116,993 shsOLYOlympia Financial GroupC$124.00-2.2%C$119.92C$95.51▼C$130.16C$298.39M0.271,918 shs1,782 shsPTFInvesco Dorsey Wright Technology Momentum ETF$69.36-1.3%$67.27$49.57▼$80.92$377.32M1.2370,454 shs77,991 shsXLYConsumer Discretionary Select Sector SPDR Fund$218.91+0.1%$217.68$169.84▼$240.28$22.23B1.184.40 million shs5.51 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-2.99%-7.30%-67.01%-68.05%-90.95%OLYOlympia Financial Group-2.25%+0.40%+2.89%+22.01%+25.25%PTFInvesco Dorsey Wright Technology Momentum ETF-1.30%-0.47%+3.69%+12.84%+29.33%XLYConsumer Discretionary Select Sector SPDR Fund+0.13%-2.54%-1.04%+9.96%+27.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.5911 of 5 stars3.50.00.00.02.90.00.0OLYOlympia Financial Group2.5152 of 5 stars2.50.02.50.00.63.31.3PTFInvesco Dorsey Wright Technology Momentum ETFN/AN/AN/AN/AN/AN/AN/AN/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.009,317.81% UpsideOLYOlympia Financial Group 3.00BuyC$147.9119.28% UpsidePTFInvesco Dorsey Wright Technology Momentum ETF 2.65Moderate Buy$69.36N/AXLYConsumer Discretionary Select Sector SPDR Fund 2.67Moderate Buy$218.91N/ACurrent Analyst Ratings BreakdownLatest PTF, OLY, AIM, and XLY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025OLYOlympia Financial GroupFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$147.91(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K15.28N/AN/A$0.20 per share14.60OLYOlympia Financial GroupC$102.64M2.91C$10.64 per share11.66C$16.72 per share7.42PTFInvesco Dorsey Wright Technology Momentum ETFN/AN/AN/AN/AN/AN/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/AOLYOlympia Financial GroupC$24.45MC$10.1612.20∞N/A23.82%64.95%35.88%N/APTFInvesco Dorsey Wright Technology Momentum ETFN/AN/A32.05∞N/AN/AN/AN/AN/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/A27.10∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AOLYOlympia Financial GroupC$7.205.81%N/A70.86%N/APTFInvesco Dorsey Wright Technology Momentum ETF$0.140.20%N/AN/AN/AXLYConsumer Discretionary Select Sector SPDR Fund$1.820.83%N/AN/AN/ALatest PTF, OLY, AIM, and XLY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/22/2025OLYOlympia Financial GroupMonthlyC$0.605.95%7/22/20257/31/20257/31/20256/19/2025OLYOlympia Financial GroupMonthlyC$0.606.28%6/19/20256/30/20256/30/20255/21/2025OLYOlympia Financial GroupMonthlyC$0.606.99%5/21/20255/30/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75OLYOlympia Financial Group6.003.321.59PTFInvesco Dorsey Wright Technology Momentum ETFN/AN/AN/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%OLYOlympia Financial Group1.17%PTFInvesco Dorsey Wright Technology Momentum ETFN/AXLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%OLYOlympia Financial Group34.63%PTFInvesco Dorsey Wright Technology Momentum ETFN/AXLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableOLYOlympia Financial Group3252.41 millionN/ANot OptionablePTFInvesco Dorsey Wright Technology Momentum ETFN/A5.44 millionN/AOptionableXLYConsumer Discretionary Select Sector SPDR Fund147,000101.55 millionN/ANot OptionablePTF, OLY, AIM, and XLY HeadlinesRecent News About These CompaniesTrump Tariff Blows Didn’t Stop These 3 Stocks From Defying Last Week’s Consumer SlumpAugust 4 at 4:03 AM | msn.comLooking for Exposure to Amazon Stock (AMZN) Post Q2 Dip? Try These Two ETFsAugust 2, 2025 | msn.comStrong Start to Q2 Earnings Season: 4 Sector ETFs to PlayJuly 30, 2025 | zacks.com4 Sector ETFs to Play on Improving Earnings TrendsJuly 28, 2025 | zacks.comEarnings Scoreboard: 12 of 17 consumer cyclical stocks beat estimates last weekJuly 27, 2025 | msn.comConsumer Durables: Overview, What They Are, ExampleJuly 25, 2025 | fool.comETFs to Consider as Consumer Sentiment Improves in JulyJuly 21, 2025 | zacks.comWeekly Economic Snapshot: Consumer Spending Rebounds Despite Rising InflationJuly 21, 2025 | etftrends.comEConsumer Stocks Post Weekly Gains As Retail Sales Rebound, Inflation Picks Up: Here Are The Top 3 WinnersJuly 21, 2025 | msn.comThe Market Rally Is Gaining Momentum—Don’t Get Left Behind (XLY)...July 17, 2025 | marketbeat.com5 Sector ETFs Set to Power Q2 Earnings GrowthJuly 10, 2025 | zacks.comS&P 500 consumer discretionary sector jumps 8.9% in Q2, Royal Caribbean Cruises, Carnival, Lululemon Athletica among top moversJuly 3, 2025 | seekingalpha.comWeekly Economic Snapshot: Record Highs Amid Rising Inflation & Conflicting SentimentJune 30, 2025 | etftrends.comENorwegian Cruise Line Stock: Is NCLH Underperforming the Consumer Discretionary Sector?June 26, 2025 | msn.comConsumer Discretionary Select Sector SPDR ETF declares quarterly distribution of $0.4470June 23, 2025 | msn.comAmcor Stock: Is AMCR Underperforming the Consumer Discretionary Sector?June 23, 2025 | finance.yahoo.comConsumer Rebound Boosts Outlook for Discretionary ETFsJune 16, 2025 | zacks.comWeekly Economic Snapshot: Inflation Edges Up While Sentiment ReboundsJune 16, 2025 | etftrends.comESector ETFs Set to Gain as Inflation Cools in MayJune 12, 2025 | zacks.comIs Consumer Discretionary a Dead End? These 3 Stocks Say No (XLY)...June 11, 2025 | marketbeat.comNintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? (XLY)...June 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportBy Jeffrey Neal Johnson | July 13, 2025View 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportAlphabet: Technical Momentum Is Starting to TurnBy Ryan Hasson | July 10, 2025View Alphabet: Technical Momentum Is Starting to TurnAnalysts Bet Big on Uber Stock's Expansion in Autonomous DrivingBy Gabriel Osorio-Mazilli | July 14, 2025View Analysts Bet Big on Uber Stock's Expansion in Autonomous DrivingPTF, OLY, AIM, and XLY Company DescriptionsAIM ImmunoTech NYSE:AIM$2.92 -0.09 (-2.99%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$2.92 0.00 (0.00%) As of 08/5/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Olympia Financial Group TSE:OLYC$124.00 -2.85 (-2.25%) As of 08/5/2025 03:59 PM EasternOlympia Financial Group Inc is engaged in providing financial services. The company's operating segments are Private Health Services Plan division which markets, sells and administers health and dental benefits to business owners; Investment Account Services division specializes in registered account administration; The Currency and Global Payments division provides corporations and private clients a personalized service for buying and selling foreign currencies; The Exempt Edge division is focused on Onboarding fees; The Corporate and Shareholder Services division, which acts as a cost centre and the Corporate Division.Invesco Dorsey Wright Technology Momentum ETF NASDAQ:PTF$69.36 -0.91 (-1.30%) Closing price 08/5/2025 03:50 PM EasternExtended Trading$69.36 0.00 (0.00%) As of 08/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PowerShares Dynamic Technology Sector Portfolio (the Fund) seeks investment results that correspond generally to the price and yield of the Dynamic Technology Sector Intellidex Index (the Index). The Index consists of stocks of the United States technology companies. These are companies that are principally engaged in the business of providing technology-related products and services, including computer hardware and software, Internet, electronics and semiconductors, and communication technologies. The Fund will invest at least 80% of its total assets in common stocks of technology companies. The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. The Find invests in various sectors, such as computers, electronics, software, semiconductors, telecommunications and commercial services. The Fund's investment adviser is Invesco PowerShares Capital Management LLC.Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$218.91 +0.28 (+0.13%) Closing price 08/5/2025 04:10 PM EasternExtended Trading$218.72 -0.19 (-0.09%) As of 08/5/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Consumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Soars After Blowout Earnings Report Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? Applied Digital: Why a Surge in Bullish Bets Signals a New Era META Gets Huge Upgrades: How High Analysts Think Shares Could Go Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
